Mometasone Furoate (MF) Sinus Implant Use in Patients with Nasal Polyps: A Descriptive Analysis

    Basic Details
    Date Posted
    Thursday, March 3, 2022
    Status
    Complete
    Medical Product
    mometasone sinus implant
    Description

    In this report we examined counts of individuals who received Sinuva or Propel, both of which are mometasone furoate (MF) sinus stents, for the treatment of nasal polyps in the Sentinel Distributed Database (SDD). Additionally, we examined these individuals further on whether or not they also had a record indicating the presence of glaucoma or cataracts in the six months prior to receiving the Sinuva MF sinus stent.

    We distributed this query to 14 Sentinel Data Partners on July 2, 2021. The study period includes data from January 1, 2016 through April 30, 2021.

     

    Additional Details
    FDA Center
    CDER
    Time Period
    January 1, 2016 - April 30, 2021
    Study Type
    Modular Program
    Assessment Type
    Exploratory Analyses
    Population / Cohort
    All individuals
    Data Sources
    Sentinel Distributed Database (SDD)